EP3976014A4 - Kombination mit alogliptin und metformin - Google Patents
Kombination mit alogliptin und metformin Download PDFInfo
- Publication number
- EP3976014A4 EP3976014A4 EP20815329.6A EP20815329A EP3976014A4 EP 3976014 A4 EP3976014 A4 EP 3976014A4 EP 20815329 A EP20815329 A EP 20815329A EP 3976014 A4 EP3976014 A4 EP 3976014A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- alogliptin
- metformin
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2019/07905A TR201907905A1 (tr) | 2019-05-24 | 2019-05-24 | Alogli̇pti̇n ve metformi̇n i̇çeren bi̇r kombi̇nasyon |
PCT/TR2020/050317 WO2020242413A1 (en) | 2019-05-24 | 2020-04-15 | A combination comprising alogliptin and metformin |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3976014A1 EP3976014A1 (de) | 2022-04-06 |
EP3976014A4 true EP3976014A4 (de) | 2023-02-15 |
Family
ID=73553852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20815329.6A Pending EP3976014A4 (de) | 2019-05-24 | 2020-04-15 | Kombination mit alogliptin und metformin |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3976014A4 (de) |
TR (1) | TR201907905A1 (de) |
WO (1) | WO2020242413A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR202022144A1 (tr) * | 2020-12-29 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Alogli̇pti̇n i̇çeren farmasöti̇k kompozi̇syonlar |
CN113081973A (zh) * | 2021-05-07 | 2021-07-09 | 郑州泰丰制药有限公司 | 一种盐酸二甲双胍组合物及其制备方法 |
WO2023059118A1 (ko) * | 2021-10-08 | 2023-04-13 | (주)셀트리온 | 안정성이 개선된 당뇨병 치료용 약학 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009011451A1 (en) * | 2007-07-19 | 2009-01-22 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
KR20150059166A (ko) * | 2015-05-12 | 2015-05-29 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
WO2017033115A1 (en) * | 2015-08-21 | 2017-03-02 | Alembic Pharmaceuticals Limited | Stable pharmaceutical composition of alogliptin and metformin fixed dose combination |
US20180235966A1 (en) * | 2015-08-20 | 2018-08-23 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of alogliptin and metformin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20091730A1 (es) * | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
WO2013179307A2 (en) | 2012-05-29 | 2013-12-05 | Mylan Laboratories Limited | Stabilized pharmaceutical compositions of saxagliptin |
-
2019
- 2019-05-24 TR TR2019/07905A patent/TR201907905A1/tr unknown
-
2020
- 2020-04-15 WO PCT/TR2020/050317 patent/WO2020242413A1/en unknown
- 2020-04-15 EP EP20815329.6A patent/EP3976014A4/de active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009011451A1 (en) * | 2007-07-19 | 2009-01-22 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
KR20150059166A (ko) * | 2015-05-12 | 2015-05-29 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
US20180235966A1 (en) * | 2015-08-20 | 2018-08-23 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of alogliptin and metformin |
WO2017033115A1 (en) * | 2015-08-21 | 2017-03-02 | Alembic Pharmaceuticals Limited | Stable pharmaceutical composition of alogliptin and metformin fixed dose combination |
Non-Patent Citations (1)
Title |
---|
See also references of WO2020242413A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3976014A1 (de) | 2022-04-06 |
TR201907905A1 (tr) | 2020-12-21 |
WO2020242413A1 (en) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3917526A4 (de) | Verbindungen und verwendungen davon | |
EP3917934A4 (de) | Verbindungen und verwendungen davon | |
EP3917529A4 (de) | Verbindungen und verwendungen davon | |
EP3917517A4 (de) | Verbindungen und verwendungen davon | |
EP3976014A4 (de) | Kombination mit alogliptin und metformin | |
EP3931561A4 (de) | Nanosensoren und verwendung davon | |
EP3917527A4 (de) | Verbindungen und verwendungen davon | |
EP3847011A4 (de) | Lamitube und implementierungen davon | |
EP3941908A4 (de) | Verbindungen und verwendungen davon | |
EP4055934A4 (de) | Design und konfiguration zur referenzsignalisierung | |
EP3745873A4 (de) | Schutz einer bioaktiven substanz und/oder eines vorläufers davon | |
EP3731837A4 (de) | Kombination aus linaglipitin und metformin | |
EP4025194A4 (de) | Kombination mit vildagliptin und metformin | |
EP3911322A4 (de) | Verbindungen und verwendungen davon | |
EP4049159A4 (de) | Verhinderung von ransomware | |
EP3999056A4 (de) | Pharmazeutische kombination und verwendung davon | |
EP4011898A4 (de) | 2-hydroxy-5-pregnan-20-on-derivate und verwendung davon | |
EP3983094A4 (de) | Verbindungsanordnung für ein trampolin und ein trampolin | |
EP3927779A4 (de) | Antimikrobielle azo-verbindungen und verwendungen davon | |
EP3914593A4 (de) | Verbindungen und verwendungen davon | |
EP3947365A4 (de) | Substituierte n-heteroaryl-verbindungen und ihre verwendungen | |
IL290003A (en) | A matrix that adheres to the tissue and its use | |
IL289602A (en) | Preparation, kit and their use | |
EP4004015A4 (de) | Teixobactin-analogon und seine verwendung | |
EP4051669A4 (de) | Ssao-inhibitoren und verwendung davon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211124 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230116 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/30 19900101ALI20230110BHEP Ipc: A61K 9/48 19740701ALI20230110BHEP Ipc: A61K 9/20 19740701ALI20230110BHEP Ipc: A61K 31/513 20000101ALI20230110BHEP Ipc: A61K 31/155 19740701AFI20230110BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230708 |